FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 304:1057-1062 April 30, 1981 Number 18 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Fifty-three profoundly granulocytopenic patients with relapsed acute leukemia who were undergoing reinduction chemotherapy were prospectively randomized to receive either trimethoprim-sulfamethoxazole plus nystatin or gentamicin plus nystatin for prevention of infections. The acquisition of new organisms per patient during the total study period was similar in both groups. Thirty-five symptomatic infections (five of which were bacteremias) occurred in patients receiving trimethoprim-sulfamethoxazole plus nystatin, whereas 31 infections (eight bacteremias) occurred in patients receiving gentamicin plus nystatin. Four deaths related to infection occurred in patients taking trimethoprim-sulfamethoxazole, and eight occurred in patients taking gentamicin. We conclude that trimethoprim-sulfamethoxazole plus nystatin was approximately as effective as gentamicin plus nystatin for prophylaxis against infection in relapsed acute leukemia. Furthermore, side effects were fewer and compliance was better with trimethoprim-sulfamethoxazole plus nystatin.

This article has been cited by other articles:

• Gafter-Gvili, A., Fraser, A., Paul, M., Leibovici, L. (2005). Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients. ANN INTERN MED 142: 979-995 [Abstract] [Full Text]  
• Velders, G. A., van Os, R., Hagoort, H., Verzaal, P., Guiot, H. F. L., Lindley, I. J. D., Willemze, R., Opdenakker, G., Fibbe, W. E. (2004). Reduced stem cell mobilization in mice receiving antibiotic modulation of the intestinal flora: involvement of endotoxins as cofactors in mobilization. Blood 103: 340-346 [Abstract] [Full Text]  
• Talcott, J. A. (1997). Outpatient Management of Febrile Neutropenia: Should We Change the Standard of Care?. The Oncologist 2: 365-373 [Abstract] [Full Text]